Sophiris Bio (NASDAQ:SPHS) received a $6.00 target price from equities research analysts at HC Wainwright in a report released on Thursday. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright’s price target would suggest a potential upside of 183.02% from the company’s current price.
Other equities research analysts have also recently issued research reports about the stock. Maxim Group set a $6.00 target price on shares of Sophiris Bio and gave the stock a “buy” rating in a research note on Monday, December 11th. ValuEngine upgraded shares of Sophiris Bio from a “strong sell” rating to a “sell” rating in a research note on Friday, December 15th. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $6.00.
Shares of Sophiris Bio stock opened at $2.12 on Thursday. Sophiris Bio has a one year low of $1.80 and a one year high of $2.95. The company has a debt-to-equity ratio of 0.84, a current ratio of 9.94 and a quick ratio of 13.37.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. raised its stake in Sophiris Bio by 1.0% during the 2nd quarter. Vanguard Group Inc. now owns 731,437 shares of the biopharmaceutical company’s stock worth $1,609,000 after acquiring an additional 7,600 shares during the period. Virtu Financial LLC raised its stake in Sophiris Bio by 389.7% during the 4th quarter. Virtu Financial LLC now owns 169,790 shares of the biopharmaceutical company’s stock worth $385,000 after acquiring an additional 135,119 shares during the period. Goldman Sachs Group Inc. bought a new stake in shares of Sophiris Bio during the fourth quarter valued at approximately $312,000. Finally, Millennium Management LLC bought a new stake in shares of Sophiris Bio during the fourth quarter valued at approximately $453,000. Institutional investors own 6.37% of the company’s stock.
About Sophiris Bio
Sophiris Bio, Inc, formerly Protox Therapeutics Inc, is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate).
Receive News & Ratings for Sophiris Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sophiris Bio and related companies with MarketBeat.com's FREE daily email newsletter.